Immutep Regains Nasdaq Compliance After ADS Ratio Adjustment

  • Immutep's ADSs closed at or above $1.00 for 10 consecutive business days (28 Sep - 9 Oct 2026), regaining Nasdaq compliance.
  • Nasdaq had previously notified Immutep on 27 April 2026 of non-compliance due to ADS price falling below $1.00 for 30 consecutive days.
  • Immutep adjusted its ADS ratio from 10:1 to 200:1 ordinary shares to address the deficiency, effective 28 September 2026.
  • The change did not affect Immutep's ordinary shares trading on the ASX under the code IMM.

Immutep's regulatory compliance restoration highlights the delicate balance biotech firms face in maintaining market listings while navigating volatile stock prices. The ADS ratio adjustment reflects a strategic move to align with Nasdaq's requirements, a common challenge for late-stage immunotherapy companies operating across multiple exchanges. This event underscores the importance of liquidity and investor confidence in sustaining market access for emerging biotech players.

Market Stability
Whether Immutep can sustain its ADS price above $1.00 to maintain Nasdaq compliance.
Operational Impact
How the ADS ratio change affects investor sentiment and trading liquidity.
Regulatory Dynamics
The pace at which Nasdaq enforces minimum bid price requirements for biotech firms.